Glioma trial of intranasal therapy NEO100 fills all patient slots
Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows…
News
WHO grants nonproprietary name to ovarian cancer cell therapy
A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The…
Carvykti label updated to include survival benefit data in myeloma
Regulators in the U.S. and Europe have approved updates to the prescribing information for Carvykti (ciltacabtagene autoleucel), a cell therapy …
FDA approves ziftomenib to treat some relapsed leukemia patients
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1…
Camera pill to find pancreatic cancer seeks breakthrough status
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as…
Tinostamustine named orphan drug for treating malignant gliomas
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend…
FDA approves 1st treatment for high-risk smoldering myeloma
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase) for adults with high-risk smoldering multiple myeloma, making it…
New combination therapy approach may improve ovarian cancer care
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data…
CAR T-cell therapy candidate yields lasting response in tough lymphoma
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with hard-to-treat large B-cell lymphoma (LBCL).
FDA speeds development of oral pancreatic cancer treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to daraxonrasib, an oral therapy being developed by Revolution Medicines to treat…
